sanofi astrazeneca - Search News

Order byBest matchMost fresh

FDA, Merck and Sanofi

Digest more

· 1d · on MSN

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

BioSpace · 23h

Merck Wins FDA Nod for RSV Antibody, Tees Up Challenge to Sanofi, AstraZeneca

Fierce Pharma · 1d

Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus

· 1d

US FDA approves Merck's RSV antibody for infants

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day.

STAT · 22h

Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more

· 1d

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

15hon MSN

Newly approved therapy could offer another option for protecting infants from RSV, a common infection that can be deadly

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

18hon MSN

AstraZeneca, BioNTech, GSK, Sanofi, Moderna, Novavax, Pfizer share prices: Why are vaccine stocks down?

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all membe

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season,

Fierce Pharma1d

Feeling RSV heat from Merck, Sanofi lays out early supply plans for Beyfortus

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., Sanofi has

pharmaphorum1d

Sanofi starts shipping RSV drug early as rival nears market

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical data than Beyfortus, and has a different molecular target. Specifically, Beyfortus is given in two different doses based on body weight, while clesrovimab is administered as a single dose regardless of weight.